BIOTECanada article in Insights Magazine features CIMTEC customer KalGene Pharmaceuticals in co-development agreement with NRC for treatment against aggressive brain cancers

The National Research Council and KalGene Pharmaceuticals recently announced an agreement to co-develop a new treatment against aggressive brain cancers.

By combining their research, NRC and KalGene are targeting glioblastomas, severe brain tumours associated with a median patient survival of about 15 months. The collaboration couples KalGene’s proprietary therapeutic antibody with NRC’s single domain antibodies to enable delivery inside the brain, a promising strategy that may lead to improved outcomes for patients. Acting as carriers, NRC’s antibodies will shuttle KalGene’s antibody across the challenging blood-brain barrier to target the tumour cells in the brain. Read full article.